ArticleThe Biochemical journal2000
Four isoforms of serum response factor that increase or inhibit smooth-muscle-specific promoter activity.
Article in The Biochemical journal, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 58 citations in OpenAlex.
- SRF: a seriously responsible factor in cardiac development and disease.Journal of biomedical science · 2022Review
- Serum response factor deletion 5 regulates phospholamban phosphorylation and calcium uptake.Journal of molecular and cellular cardiology · 2021Article
- SRF phosphorylation by glycogen synthase kinase-3 promotes axon growth in hippocampal neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- Mechano-regulation of alternative splicing.Current genomics · 2013Article
- Identification of New SRF Binding Sites in Genes Modulated by SRF Over-Expression in Mouse Hearts.Gene regulation and systems biology · 2011Article
- Characteristics of the CArG-SRF binding context in mammalian genomes.Mammalian genome : official journal of the International Mammalian Genome Society · 2010Article
- Regulation of SRF/CArG-dependent gene transcription during chronic partial obstruction of murine small intestine.Neurogastroenterology and motility · 2008Article
- Embryological origin of airway smooth muscle.Proceedings of the American Thoracic Society · 2008Review
- Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- 5' CArG degeneracy in smooth muscle alpha-actin is required for injury-induced gene suppression in vivo.The Journal of clinical investigation · 2005Article
- Selective modulation of the SM22alpha promoter by the binding of BTEB3 (basal transcription element-binding protein 3) to TGGG repeats.The Biochemical journal · 2003Article
- Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation.Molecular and cellular biology · 2003Article
- Increased actin polymerization reduces the inhibition of serum response factor activity by Yin Yang 1.The Biochemical journal · 2002Article
- High RhoA activity maintains the undifferentiated mesenchymal cell phenotype, whereas RhoA down-regulation by laminin-2 induces smooth muscle myogenesis.The Journal of cell biology · 2002Article
- Stretch-induced alternative splicing of serum response factor promotes bronchial myogenesis and is defective in lung hypoplasia.The Journal of clinical investigation · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum response factor (SRF) is a key transcriptional activator of the c-fos gene and of muscle-specific gene expression. We have identified four forms of the SRF coding sequence, SRF-L (the previously identified form), SRF-M, SRF-S and SRF-I, that are produced by alternative splicing. The new forms of SRF lack regions of the C-terminal transactivation domain by splicing out of exon 5 (SRF-M), exons 4 and 5 (SRF-S) and exons 3, 4 and 5 (SRF-I). SRF-M is expressed at similar levels to SRF-L in differentiated vascular smooth-muscle cells and skeletal-muscle cells, whereas SRF-L is the predominant form in many other tissues. SRF-S expression is restricted to vascular smooth muscle and SRF-I expression is restricted to the embryo. Transfection of SRF-L and SRF-M into C(2)C(12) cells showed that both forms are transactivators of the promoter of the smooth-muscle-specific gene SM22alpha, whereas SRF-I acted as a dominant negative form of SRF.
Indexed as
Identifiers
10642500PMC1220776W2069915481What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.